
Jaeok Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6310142/publications.pdf Version: 2024-02-01



INFOR DADE

#	Article	IF	CITATIONS
1	Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (CGPP) biosynthesis and its implication in the treatment of cancers. Critical Reviews in Biochemistry and Molecular Biology, 2019, 54, 41-60.	5.2	52
2	Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells. Journal of Medicinal Chemistry, 2012, 55, 3201-3215.	6.4	46
3	Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition. Journal of Medicinal Chemistry, 2013, 56, 7939-7950.	6.4	43
4	Human isoprenoid synthase enzymes as therapeutic targets. Frontiers in Chemistry, 2014, 2, 50.	3.6	37
5	Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 6904-6917.	6.4	33
6	Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product. Nature Communications, 2017, 8, 14132.	12.8	32
7	Maintenance of Native-like Protein Dynamics May Not Be Required for Engineering Functional Proteins. Chemistry and Biology, 2014, 21, 1330-1340.	6.0	29
8	Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2014, 57, 5764-5776.	6.4	29
9	Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure. BMC Structural Biology, 2012, 12, 32.	2.3	21
10	Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 2017, 60, 2119-2134.	6.4	21
11	A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome. Neurobiology of Disease, 2019, 121, 187-204.	4.4	21
12	Structural and functional insights into esterase-mediated macrolide resistance. Nature Communications, 2021, 12, 1732.	12.8	21
13	The Structural Dynamics of Engineered β-Lactamases Vary Broadly on Three Timescales yet Sustain Native Function. Scientific Reports, 2019, 9, 6656.	3.3	19
14	Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective. Frontiers in Chemistry, 2020, 8, 612728.	3.6	19
15	Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1117-1123.	2.2	15
16	Assorted dysfunctions of endosomal alkali cation/proton exchanger SLC9A6 variants linked to Christianson syndrome. Journal of Biological Chemistry, 2020, 295, 7075-7095.	3.4	13
17	Chirality-Driven Mode of Binding of α-Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS). Journal of Medicinal Chemistry, 2019, 62, 9691-9702.	6.4	10
18	Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 299-304.	0.8	9

Jaeok Park

#	Article	IF	CITATIONS
19	Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2′) enzymes. Scientific Reports, 2021, 11, 11614.	3.3	9
20	Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase. PLoS ONE, 2017, 12, e0186447.	2.5	5
21	Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 2022, 65, 2471-2496.	6.4	5
22	Crystal structures of hFPPS in complex with novel anticancer drug leads. Acta Crystallographica Section A: Foundations and Advances, 2014, 70, C712-C712.	0.1	0
23	Revisiting the Catalytic Cycle and Kinetic Mechanism of Aminoglycoside <i>O</i> -Nucleotidyltransferase(2″): A Structural and Kinetic Study. ACS Chemical Biology, 2020, 15, 686-694.	3.4	0